Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022

被引：0
|
作者：
Tibau, A. [1 ]
Hwang, T. J. [2 ]
Consolacion, M. [3 ]
Avorn, J. [4 ]
Kesselheim, A. [4 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Brigham & Womens Hosp, Div Urol Surg, Boston, TX USA
[3] Princess Margaret Canc Ctr, Med Oncol Dept, Toronto, ON, Canada
[4] Brigham & Womens Hosp, PORTAL Program Regulat Therapeut & Law, Pharmacoepidemiol & Pharmacoecomon Div, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1703P
引用
收藏
页码：S930 / S930
页数：1
相关论文
共 49 条
  • [21] Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents
    Shi, Wenjie
    Li, Chen
    Wartmann, Thomas
    Kahlert, Christoph
    Du, Renfei
    Perrakis, Aristotelis
    Brunner, Thomas
    Croner, Roland S.
    Kahlert, Ulf D.
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (03):
  • [22] Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015
    Vivot, A.
    Jacot, J.
    Zeitoun, J. -D.
    Ravaud, P.
    Crequit, P.
    Porcher, R.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1111 - 1116
  • [23] Adoption of newly FDA-approved targeted immunomodulatory therapies for Plaque Psoriasis by Dermatologists: An analysis of Medicare Part D claims from 2013-2018
    Dean, Owen
    Tausk, Francisco
    Singh, Partik
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB14 - AB14
  • [24] Adoption of newly FDA-approved targeted immunomodulatory therapies by dermatologists: a cross-sectional analysis of Medicare Part D claims from 2013 to 2018
    Dean, Owen
    Tausk, Francisco
    Singh, Partik
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2023, 315 (03) : 673 - 676
  • [25] Adoption of newly FDA-approved targeted immunomodulatory therapies by dermatologists: a cross-sectional analysis of Medicare Part D claims from 2013 to 2018
    Owen Dean
    Francisco Tausk
    Partik Singh
    Archives of Dermatological Research, 2023, 315 : 673 - 676
  • [26] Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs
    Ishola, Ahmed A.
    Adewole, Kayode E.
    Tijjani, Habibu
    Abdulai, Suliat, I
    Asogwa, Nnaemeka T.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (17): : 7726 - 7743
  • [27] Prime time for prospective randomized trials of targeted therapies with validated targets in lung cancer: FDA perspective
    Malik, Shakun
    Justice, Robert
    Sridhara, Rajeshwari
    Waxman, Ian
    Pazdur, Richard
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : S235 - S236
  • [28] The FDA-Approved Drug Pyrvinium Selectively Targets ER+ Breast Cancer Cells with High INPP4B Expression
    Rodgers, Samuel J.
    Ooms, Lisa M.
    Mitchell, Christina A.
    CANCERS, 2023, 15 (01)
  • [29] Synthetic Lethality of K-Ras Mutant Human Colorectal Cancer Cells by Phytochemical Curcumin and FDA-Approved Targeted Drug Regorafenib
    Su, Chun-Li
    Wu, Chi-Shiuan
    FASEB JOURNAL, 2017, 31
  • [30] Immune modulation by molecular cancer targets and targeted therapies Rationale for novel combination strategies
    Rossig, Claudia
    ONCOIMMUNOLOGY, 2012, 1 (03) : 358 - 360
12345